Long-term estimate of quality-adjusted life expectancy for nilotinib and imatinib as first-line treatment for newly diagnosed patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in the chronic phase (CML-CP)

Botteman, M. ; Stephens, J. ; Snedecor, S. J. ; Ji, X. ; Hussein, M. ; Coombs, J.

Texto completo disponível

Changing characteristics and improved outcome of early breast cancer in low- and middle-income countries

El-Saghir, N. S. ; Mikdachi, H. ; Nachef, Z. ; El Asmar, N. ; Sibai, H. ; Boulos, F. ; Abbas, J. ; Hussein, M. ; Jamali, F. ; Berjawi, G. ; Bikhazi, K. J. ; Eid, T.

Texto completo disponível

A phase II trial of sorafenib in patients with relapsing and resistant multiple myeloma (MM) previously treated with bortezomib (S0434)

Srkalovic, G. ; Hussein, M. ; Bolejack, V. ; Hoering, A. ; Zonder, J. ; Barlogie, B.

Texto completo disponível

Postradiation therapy sarcoma

Mourad, W. F. ; Saad, A. A. ; Packianathan, S. ; Zhang, Z. ; Shourbaji, R. A. ; Caudell, J. J. ; Jennelle, R. L. ; Baird, M. C. ; Vijayakumar, S. ; Hussein, M. A.

Texto completo disponível

Phase II study of pegylated liposomal doxorubicin (PLD), low-dose dexamethasone (DEX), and lenalidomide (LEN) in patients with newly diagnosed (ND) multiple myeloma (MM)

Baz, R. ; Hussein, M. A. ; Sullivan, D. ; Raychaudhuri, J. ; Ochoa, L. ; Kosakowski, K. ; Nardelli, L. ; Dalton, W. S. ; Alsina, M.

Texto completo disponível

Vorinostat-based therapy for solid or hematologic malignancies: The combined safety and tolerability profile

Siegel, D. S. ; Rubin, E. H. ; VanBelle, S. ; Hussein, M. A. ; Belani, C. P. ; Robert, F. ; Galanis, E. ; Boileau, K. T. ; Eid, J. E. ; Graef, T.

Texto completo disponível

Final analysis of MM-014: Single-agent lenalidomide in patients with relapsed and refractory multiple myeloma

Hussein, M. A. ; Richardson, P. G. ; Jagannath, S. ; Singhal, S. ; Bensinger, W. ; Knight, R. ; Zeldis, J. B. ; Yu, Z. ; Olesnyckyj, M. ; Anderson, K. C.

Texto completo disponível

A randomized Southwest Oncology Group study comparing dexamethasone (D) to lenalidomide + dexamethasone (LD) as treatment of newly-diagnosed multiple myeloma (NDMM): Impact of cytogenetic abnormalities on efficacy of LD, and updated overall study results

Zonder, J. A. ; Crowley, J. J. ; Bolejack, V. ; Hussein, M. A. ; Moore, D. F. ; Whittenberger, B. F. ; Abidi, M. H. ; Durie, B. G. ; Barlogie, B.

Texto completo disponível

Safety and tolerability of vorinostat—Experience from the vorinostat clinical trial program

Siegel, D. S. ; Hussein, M. A. ; Belani, C. P. ; Robert, F. ; Rizvi, S. ; Wigginton, J. ; Randolph, S. ; Crane, R. ; Ganesan, R. ; Garcia-Vargas, J.

Texto completo disponível

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial

Demetri, George D ; von Mehren, Margaret ; Jones, Robin L ; Hensley, Martee L ; Schuetze, Scott M ; Staddon, Arthur ; Milhem, Mohammed ; Elias, Anthony ; Ganjoo, Kristen ; Tawbi, Hussein ; Van Tine, Brian A ; Spira, Alexander ; Dean, Andrew ; Khokhar, Nushmia Z ; Park, Youn Choi ; Knoblauch, Roland E ; Parekh, Trilok V ; Maki, Robert G ; Patel, Shreyaskumar R

United States: American Society of Clinical Oncology

Texto completo disponível